Key statistics
On Friday, Aligos Therapeutics Inc (ALGS:NAQ) closed at 20.04, -33.20% below its 52-week high of 30.00, set on Mar 04, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 20.01 |
---|---|
High | 20.44 |
Low | 18.75 |
Bid | 19.50 |
Offer | 20.20 |
Previous close | 19.79 |
Average volume | 1.11m |
---|---|
Shares outstanding | 3.59m |
Free float | 2.85m |
P/E (TTM) | -- |
Market cap | 71.00m USD |
EPS (TTM) | -18.70 USD |
Data delayed at least 15 minutes, as of Nov 22 2024 21:00 GMT.
More ▼
Announcements
- Aligos Therapeutics Presents Positive Data at The Liver Meeting (TLM) 2024
- Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results
- Aligos Therapeutics to Announce 3rd Quarter 2024 Financial Results on November 6, 2024
- Aligos Therapeutics Announces U.S. FDA Clearance of IND Application for ALG-000184
- Aligos Therapeutics Announces Acceptance of Abstracts on Incremental Data from ALG-000184 in CHB Subjects and Late-Breaker Oral Presentation of Data from the Phase 2a HERALD Study of ALG-055009 in MASH Subjects at The Liver Meeting (TLM) 2024
- Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Aligos Therapeutics Appoints David Perry as Vice President of Business Development
- Aligos Therapeutics to Present at Investor Conferences in October
- Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer
- Aligos Therapeutics Announces Positive Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH
More ▼